Trade Biodesix, Inc. - BDSX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.0364 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Biodesix Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 1.5868 |
| Open* | 1.5968 |
| 1-Year Change* | 21.17% |
| Day's Range* | 1.5168 - 1.6168 |
| 52 wk Range | 1.03-2.53 |
| Average Volume (10 days) | 29.33K |
| Average Volume (3 months) | 1.48M |
| Market Cap | 119.43M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 90.48M |
| Revenue | 44.03M |
| EPS | -0.90 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 4, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 7, 2023 | 1.5868 | 0.0400 | 2.59% | 1.5468 | 1.6168 | 1.4968 |
| Dec 6, 2023 | 1.4868 | 0.0200 | 1.36% | 1.4668 | 1.6168 | 1.4368 |
| Dec 5, 2023 | 1.4868 | 0.0300 | 2.06% | 1.4568 | 1.4968 | 1.4468 |
| Dec 4, 2023 | 1.4768 | 0.0300 | 2.07% | 1.4468 | 1.4868 | 1.4268 |
| Dec 1, 2023 | 1.4468 | -0.0600 | -3.98% | 1.5068 | 1.5168 | 1.3768 |
| Nov 30, 2023 | 1.4568 | 0.0100 | 0.69% | 1.4468 | 1.4868 | 1.4268 |
| Nov 29, 2023 | 1.4868 | -0.0100 | -0.67% | 1.4968 | 1.4968 | 1.4568 |
| Nov 28, 2023 | 1.4768 | 0.0200 | 1.37% | 1.4568 | 1.4768 | 1.4168 |
| Nov 27, 2023 | 1.4568 | -0.0300 | -2.02% | 1.4868 | 1.4868 | 1.4568 |
| Nov 24, 2023 | 1.4868 | 0.0300 | 2.06% | 1.4568 | 1.5068 | 1.4568 |
| Nov 22, 2023 | 1.4268 | 0.0600 | 4.39% | 1.3668 | 1.4868 | 1.3668 |
| Nov 21, 2023 | 1.3168 | -0.0700 | -5.05% | 1.3868 | 1.3968 | 1.2468 |
| Nov 20, 2023 | 1.3968 | -0.0200 | -1.41% | 1.4168 | 1.4268 | 1.3768 |
| Nov 17, 2023 | 1.3868 | -0.0500 | -3.48% | 1.4368 | 1.4468 | 1.3668 |
| Nov 16, 2023 | 1.3968 | 0.0000 | 0.00% | 1.3968 | 1.4168 | 1.3768 |
| Nov 15, 2023 | 1.4268 | 0.1200 | 9.18% | 1.3068 | 1.4268 | 1.3068 |
| Nov 14, 2023 | 1.3268 | 0.0600 | 4.74% | 1.2668 | 1.3268 | 1.2668 |
| Nov 13, 2023 | 1.2568 | -0.0400 | -3.08% | 1.2968 | 1.2968 | 1.2268 |
| Nov 10, 2023 | 1.1968 | -0.0400 | -3.23% | 1.2368 | 1.2468 | 1.1568 |
| Nov 9, 2023 | 1.2368 | -0.0600 | -4.63% | 1.2968 | 1.3268 | 1.2268 |
Biodesix, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, March 4, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Biodesix Inc Earnings Release Q4 2023 Biodesix Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 38.212 | 54.506 | 45.557 | 24.552 | 20.432 |
| Revenue | 38.212 | 54.506 | 45.557 | 24.552 | 20.432 |
| Cost of Revenue, Total | 14.154 | 30.518 | 21.998 | 6.074 | 4.406 |
| Gross Profit | 24.058 | 23.988 | 23.559 | 18.478 | 16.026 |
| Total Operating Expense | 95.78 | 93.148 | 68.491 | 51.293 | 44.095 |
| Selling/General/Admin. Expenses, Total | 58.458 | 47.958 | 32.328 | 30.637 | 25.899 |
| Research & Development | 13.102 | 12.789 | 10.818 | 10.468 | 8.188 |
| Unusual Expense (Income) | 7.062 | -2.298 | 3.451 | 1.739 | |
| Other Operating Expenses, Total | 0 | 1.622 | 0.818 | 0.663 | 3.863 |
| Operating Income | -57.568 | -38.642 | -22.934 | -26.741 | -23.663 |
| Interest Income (Expense), Net Non-Operating | -8.072 | -4.508 | -7.586 | -2.953 | -2.892 |
| Other, Net | 0.193 | -0.009 | -0.83 | -1.032 | 0.389 |
| Net Income Before Taxes | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Net Income After Taxes | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Net Income Before Extra. Items | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Net Income | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Income Available to Common Excl. Extra. Items | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Income Available to Common Incl. Extra. Items | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Diluted Net Income | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Diluted Weighted Average Shares | 42.103 | 27.365 | 26.5615 | 26.2541 | 26.2541 |
| Diluted EPS Excluding Extraordinary Items | -1.55445 | -1.57716 | -1.18028 | -1.17033 | -0.99665 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -1.38672 | -1.66114 | -1.14948 | -1.03889 | -0.93041 |
| Depreciation / Amortization | 3.004 | 2.559 | 2.529 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 11.872 | 9.056 | 9.607 | 11.107 | 10.95 |
| Revenue | 11.872 | 9.056 | 9.607 | 11.107 | 10.95 |
| Cost of Revenue, Total | 3.238 | 3.169 | 3.306 | 3.633 | 3.98 |
| Gross Profit | 8.634 | 5.887 | 6.301 | 7.474 | 6.97 |
| Total Operating Expense | 22.799 | 25.429 | 27.474 | 21.769 | 25.528 |
| Selling/General/Admin. Expenses, Total | 16.651 | 18.989 | 16.626 | 15.114 | 15.235 |
| Research & Development | 2.91 | 3.251 | 3.565 | 2.97 | 3.361 |
| Unusual Expense (Income) | 0 | 0.02 | 3.977 | 0.052 | 2.952 |
| Operating Income | -10.927 | -16.373 | -17.867 | -10.662 | -14.578 |
| Interest Income (Expense), Net Non-Operating | -2.43 | -2.391 | -2.55 | -3.039 | -1.346 |
| Other, Net | 0.001 | 0.062 | 0.079 | 0.002 | 0.1 |
| Net Income Before Taxes | -13.356 | -18.702 | -20.338 | -13.699 | -15.824 |
| Net Income After Taxes | -13.356 | -18.702 | -20.338 | -13.699 | -15.824 |
| Net Income Before Extra. Items | -13.356 | -18.702 | -20.338 | -13.699 | -15.824 |
| Net Income | -13.356 | -18.702 | -20.338 | -13.699 | -15.824 |
| Income Available to Common Excl. Extra. Items | -13.356 | -18.702 | -20.338 | -13.699 | -15.824 |
| Income Available to Common Incl. Extra. Items | -13.356 | -18.702 | -20.338 | -13.699 | -15.824 |
| Diluted Net Income | -13.356 | -18.702 | -20.338 | -13.699 | -15.824 |
| Diluted Weighted Average Shares | 78.506 | 77.765 | 57.553 | 40.448 | 39.239 |
| Diluted EPS Excluding Extraordinary Items | -0.17013 | -0.24049 | -0.35338 | -0.33868 | -0.40327 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.17013 | -0.24024 | -0.28428 | -0.3374 | -0.32804 |
| Other Operating Expenses, Total | 0 | 0 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 53.334 | 43.613 | 86.14 | 12.7 | 9.913 |
| Cash and Short Term Investments | 43.088 | 32.712 | 62.126 | 5.286 | 5.914 |
| Cash & Equivalents | 43.088 | 32.712 | 62.126 | 5.286 | 5.914 |
| Total Receivables, Net | 5.065 | 3.656 | 15.304 | 5.292 | 1.892 |
| Accounts Receivable - Trade, Net | 5.065 | 3.656 | 15.304 | 5.292 | 1.892 |
| Other Current Assets, Total | 5.181 | 7.245 | 8.71 | 2.122 | 2.107 |
| Total Assets | 92.906 | 76.097 | 121.07 | 41.633 | 39.057 |
| Property/Plant/Equipment, Total - Net | 8.821 | 4.179 | 3.178 | 2.12 | 1.388 |
| Property/Plant/Equipment, Total - Gross | 15.839 | 10.928 | 9.902 | 8.506 | 6.956 |
| Accumulated Depreciation, Total | -7.018 | -6.749 | -6.724 | -6.386 | -5.568 |
| Goodwill, Net | 15.031 | 15.031 | 15.031 | 11.631 | 10.804 |
| Intangibles, Net | 9.797 | 11.617 | 13.26 | 15.092 | 16.852 |
| Other Long Term Assets, Total | 5.923 | 1.657 | 3.461 | 0.09 | 0.1 |
| Total Current Liabilities | 22.839 | 28.96 | 32.125 | 22.6 | 4.468 |
| Accounts Payable | 1.685 | 1.662 | 8.964 | 1.717 | 0.886 |
| Accrued Expenses | 7.446 | 4.899 | 4.69 | 1.899 | 1.568 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 12.045 | 0 |
| Other Current Liabilities, Total | 13.659 | 22.38 | 6.631 | 6.939 | 2.014 |
| Total Liabilities | 72.3 | 56.37 | 79.904 | 76.213 | 53.125 |
| Total Long Term Debt | 25.004 | 9.993 | 15.926 | 23.812 | 23.099 |
| Long Term Debt | 25.004 | 9.993 | 15.926 | 23.812 | 23.099 |
| Other Liabilities, Total | 24.457 | 17.417 | 31.853 | 29.801 | 25.558 |
| Total Equity | 20.606 | 19.727 | 41.166 | -34.58 | -14.068 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 193.959 | 183.962 |
| Common Stock | 0.078 | 0.031 | 0.027 | 0.001 | 0.001 |
| Additional Paid-In Capital | 387.948 | 321.669 | 299.953 | 2.324 | 2.107 |
| Retained Earnings (Accumulated Deficit) | -367.42 | -301.973 | -258.814 | -230.864 | -200.138 |
| Total Liabilities & Shareholders’ Equity | 92.906 | 76.097 | 121.07 | 41.633 | 39.057 |
| Total Common Shares Outstanding | 77.6144 | 30.7896 | 26.5615 | 26.2541 | 26.2541 |
| Current Port. of LT Debt/Capital Leases | 0.049 | 0.019 | 11.84 | 0 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 28.886 | 25.245 | 34.784 | 53.334 | 24.118 |
| Cash and Short Term Investments | 19.841 | 17.409 | 25.275 | 43.088 | 15.175 |
| Cash & Equivalents | 19.841 | 17.409 | 25.275 | 43.088 | 15.175 |
| Total Receivables, Net | 5.777 | 4.119 | 4.901 | 5.065 | 4.449 |
| Accounts Receivable - Trade, Net | 5.777 | 4.119 | 4.901 | 5.065 | 4.449 |
| Other Current Assets, Total | 3.268 | 3.717 | 4.608 | 5.181 | 4.494 |
| Total Assets | 86.786 | 77.623 | 80.793 | 92.906 | 63.198 |
| Property/Plant/Equipment, Total - Net | 27.488 | 21.488 | 15.291 | 8.821 | 7.734 |
| Property/Plant/Equipment, Total - Gross | 35.364 | 29.079 | 22.599 | 15.839 | 15.151 |
| Accumulated Depreciation, Total | -7.876 | -7.591 | -7.308 | -7.018 | -7.417 |
| Goodwill, Net | 15.031 | 15.031 | 15.031 | 15.031 | 15.031 |
| Intangibles, Net | 8.416 | 8.871 | 9.311 | 9.797 | 10.223 |
| Other Long Term Assets, Total | 6.965 | 6.988 | 6.376 | 5.923 | 6.092 |
| Total Current Liabilities | 32.649 | 27.951 | 22.098 | 22.839 | 37.415 |
| Accounts Payable | 2.904 | 3.501 | 1.563 | 1.685 | 2.1 |
| Accrued Expenses | 5.68 | 6.687 | 6.027 | 7.446 | 6.017 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.05 | 0.05 | 0.05 | 0.049 | 14.334 |
| Other Current Liabilities, Total | 24.015 | 17.713 | 14.458 | 13.659 | 14.964 |
| Total Liabilities | 88.232 | 84.616 | 76.243 | 72.3 | 66.101 |
| Total Long Term Debt | 24.95 | 24.658 | 25.084 | 25.004 | 4.88 |
| Long Term Debt | 24.95 | 24.658 | 25.084 | 25.004 | 4.88 |
| Other Liabilities, Total | 30.633 | 32.007 | 29.061 | 24.457 | 23.806 |
| Total Equity | -1.446 | -6.993 | 4.55 | 20.606 | -2.903 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.088 | 0.079 | 0.078 | 0.078 | 0.041 |
| Additional Paid-In Capital | 408.893 | 392.406 | 390.594 | 387.948 | 344.138 |
| Retained Earnings (Accumulated Deficit) | -410.427 | -399.478 | -386.122 | -367.42 | -347.082 |
| Total Liabilities & Shareholders’ Equity | 86.786 | 77.623 | 80.793 | 92.906 | 63.198 |
| Total Common Shares Outstanding | 88.3158 | 78.6107 | 77.9794 | 77.6144 | 41.1855 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -65.447 | -43.159 | -31.35 | -30.726 | -26.166 |
| Cash From Operating Activities | -44.972 | -28.223 | -21.366 | -21.726 | -17.677 |
| Cash From Operating Activities | 3.597 | 3.178 | 2.903 | 2.793 | 1.74 |
| Non-Cash Items | 20.316 | 7.167 | 11.882 | 7.852 | 6.496 |
| Changes in Working Capital | -3.438 | 4.591 | -4.801 | -1.645 | 0.253 |
| Cash From Investing Activities | -3.534 | -2.547 | -2.927 | -1.872 | -0.617 |
| Capital Expenditures | -3.534 | -2.547 | -2.177 | -1.416 | -0.617 |
| Other Investing Cash Flow Items, Total | 0 | -0.75 | -0.456 | 0 | |
| Cash From Financing Activities | 58.882 | 1.262 | 81.131 | 22.972 | 19.032 |
| Financing Cash Flow Items | -17.423 | -0.5 | -8.249 | -0.119 | -0.283 |
| Issuance (Retirement) of Stock, Net | 59.807 | 17.112 | 73.34 | 10.047 | 8.55 |
| Issuance (Retirement) of Debt, Net | 16.498 | -15.35 | 16.04 | 13.044 | 10.765 |
| Net Change in Cash | 10.376 | -29.508 | 56.838 | -0.626 | 0.738 |
| Cash Interest Paid | 1.009 | 1.676 | 1.844 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -18.702 | -65.447 | -45.109 | -31.41 | -15.586 |
| Cash From Operating Activities | -7.686 | -44.972 | -33.024 | -22.693 | -13.099 |
| Cash From Operating Activities | 0.785 | 3.597 | 2.699 | 1.806 | 0.908 |
| Non-Cash Items | 4.555 | 20.316 | 13.452 | 8.61 | 2.674 |
| Changes in Working Capital | 5.676 | -3.438 | -4.066 | -1.699 | -1.095 |
| Cash From Investing Activities | -7.706 | -3.534 | -1.547 | -0.732 | -0.352 |
| Capital Expenditures | -7.706 | -3.534 | -1.547 | -0.732 | -0.352 |
| Other Investing Cash Flow Items, Total | |||||
| Cash From Financing Activities | -2.421 | 58.882 | 17.034 | 19.299 | -2.834 |
| Financing Cash Flow Items | -2.415 | -17.423 | -11.145 | -9.005 | -4.6 |
| Issuance (Retirement) of Stock, Net | 0.006 | 59.807 | 18.115 | 16.227 | 1.674 |
| Issuance (Retirement) of Debt, Net | -0.012 | 16.498 | 10.064 | 12.077 | 0.092 |
| Net Change in Cash | -17.813 | 10.376 | -17.537 | -4.126 | -16.285 |
| Cash Interest Paid | 1.032 | 1.009 | 0.473 | 0.344 | 0.223 |
| Cash Taxes Paid | 0 | 0 | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Schuler (Jack W) | Individual Investor | 38.8981 | 30579359 | 10190170 | 2023-08-03 | LOW |
| Kennedy (Lawrence T Jr.) | Individual Investor | 26.7131 | 21000243 | 6172839 | 2023-08-03 | LOW |
| Patience (John) | Individual Investor | 9.3219 | 7328336 | 308641 | 2023-08-03 | LOW |
| Birchview Capital, LP | Investment Advisor | 6.4106 | 5039633 | 0 | 2023-06-30 | LOW |
| AIGH Capital Management, LLC. | Private Equity | 4.8311 | 3797936 | -386403 | 2023-06-30 | MED |
| Cawthorn (Robert E) | Individual Investor | 4.6458 | 3652220 | 1723341 | 2022-11-21 | |
| Strobeck (Matthew W) | Individual Investor | 3.8574 | 3032445 | 127777 | 2023-08-03 | |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.644 | 1292439 | 61597 | 2023-06-30 | LOW |
| Worth Venture Partners, LLC | Investment Advisor/Hedge Fund | 1.6072 | 1263491 | -96701 | 2023-06-30 | HIGH |
| Essex Investment Management Company, LLC | Investment Advisor/Hedge Fund | 1.313 | 1032213 | 246561 | 2023-06-30 | LOW |
| Wells Fargo Advisors | Research Firm | 1.0712 | 842138 | 40197 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.5152 | 405042 | 9397 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4701 | 369552 | 134585 | 2023-06-30 | LOW |
| Legato Capital Management LLC | Investment Advisor | 0.4253 | 334310 | -19647 | 2023-09-30 | HIGH |
| Hutton Scott | Individual Investor | 0.4045 | 318013 | 77291 | 2023-08-10 | MED |
| Massarany (Hany) | Individual Investor | 0.38 | 298707 | 160773 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3503 | 275350 | 251300 | 2023-06-30 | LOW |
| Watts (Charles McDonald) | Individual Investor | 0.2979 | 234166 | 12345 | 2023-08-03 | |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.2926 | 230000 | 50600 | 2023-06-30 | MED |
| Cannell & Co. | Investment Advisor | 0.2615 | 205605 | 0 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Biodesix, Inc. Company profile
About Biodesix Inc
Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Biodesix Inc revenues increased 20% to $54.5M. Net loss increased 38% to $43.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales, marketing, general and administ increase of 49% to $43.6M (expense), Research and development - Balancing v increase of 19% to $12.2M (expense).
| Industry: | Medical & Diagnostic Laboratories |
Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com